JMP Securities Sticks to Their Buy Rating for Inovio Pharmaceuticals (INO)
JMP Securities analyst Roy Buchanan reiterated a Buy rating on Inovio Pharmaceuticals (INO – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $2.10.
Light Up your Portfolio with Spark:
- Easily identify stocks' risks and opportunities.
- Discover stocks' market position with detailed competitor analyses.
According to TipRanks, Buchanan is an analyst with an average return of -27.3% and a 26.55% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as AN2 Therapeutics, Inc., Inovio Pharmaceuticals, and Arbutus Biopharma.
Currently, the analyst consensus on Inovio Pharmaceuticals is a Moderate Buy with an average price target of $7.50.
The company has a one-year high of $14.75 and a one-year low of $1.74. Currently, Inovio Pharmaceuticals has an average volume of 860.5K.
Read More on INO:
Questions or Comments about the article? Write to editor@tipranks.com- Inovio Pharmaceuticals Reports 2024 Financial Results
- Inovio reports Q4 EPS (65c), consensus (83c)
- Inovio options imply 8.1% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, March 18, 2025
- Options Volatility and Implied Earnings Moves This Week, March 17 – March 21, 2025
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.